Histogenics

Описание: Adam Gridley, President and CEO
Waltham, MA
(NASDAQ: HSGX)

Histogenics is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart, is designed to rebuild a patient’s knee cartilage to treat pain at the source and possibly prevent the progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics completed enrollment of its NeoCart Phase III clinical trial and expects to report top-line, one-year superiority data in Q3 of this year. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.

http://www.histogenics.com